United States (US) Therapeutic Vaccines Market (2025-2031) | Competitive Landscape, Segmentation, Analysis, Companies, Forecast, Outlook, Growth, Value, Size & Revenue, Trends, Industry, Share

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) Therapeutic Vaccines Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) Therapeutic Vaccines Market - Industry Life Cycle

3.4 United States (US) Therapeutic Vaccines Market - Porter's Five Forces

3.5 United States (US) Therapeutic Vaccines Market Revenues & Volume Share, By Type, 2021 & 2031F

3.6 United States (US) Therapeutic Vaccines Market Revenues & Volume Share, By Therapeutic Vaccines, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of chronic diseases in the US, driving the demand for therapeutic vaccines.

4.2.2 Growing focus on preventive healthcare and vaccination programs by the US government and healthcare providers.

4.2.3 Technological advancements in vaccine development leading to more effective therapeutic vaccines.

4.3 Market Restraints

4.3.1 Stringent regulatory requirements and lengthy approval processes for therapeutic vaccines in the US.

4.3.2 High costs associated with the development and production of therapeutic vaccines.

4.3.3 Limited awareness and understanding of therapeutic vaccines among healthcare professionals and patients.

6.1 United States (US) Therapeutic Vaccines Market, By Type

6.1.1 Overview and Analysis

6.1.2 United States (US) Therapeutic Vaccines Market Revenues & Volume, By Type, 2021- 2031F

6.1.3 United States (US) Therapeutic Vaccines Market Revenues & Volume, By Peptide Therapeutic Vaccine, 2021- 2031F

6.1.4 United States (US) Therapeutic Vaccines Market Revenues & Volume, By Cell Therapeutic Vaccine, 2021- 2031F

6.1.5 United States (US) Therapeutic Vaccines Market Revenues & Volume, By Nucleic Acid Therapeutic Vaccine, 2021- 2031F

6.2 United States (US) Therapeutic Vaccines Market, By Therapeutic Vaccines

6.2.1 Overview and Analysis

6.2.2 United States (US) Therapeutic Vaccines Market Revenues & Volume, By Oncotherapy, 2021- 2031F

6.2.3 United States (US) Therapeutic Vaccines Market Revenues & Volume, By Hepatitis B, 2021- 2031F

6.2.4 United States (US) Therapeutic Vaccines Market Revenues & Volume, By Tuberculosis, 2021- 2031F

6.2.5 United States (US) Therapeutic Vaccines Market Revenues & Volume, By Herpes Simplex Virus, 2021- 2031F

6.2.6 United States (US) Therapeutic Vaccines Market Revenues & Volume, By Others, 2021- 2031F

7.1 United States (US) Therapeutic Vaccines Market Export to Major Countries

7.2 United States (US) Therapeutic Vaccines Market Imports from Major Countries

8.1 Patient engagement and adherence rates to therapeutic vaccine regimens.

8.2 Clinical trial success rates for new therapeutic vaccines.

8.3 Adoption rates of therapeutic vaccines in targeted patient populations.

9.1 United States (US) Therapeutic Vaccines Market Opportunity Assessment, By Type, 2021 & 2031F

9.2 United States (US) Therapeutic Vaccines Market Opportunity Assessment, By Therapeutic Vaccines, 2021 & 2031F

10.1 United States (US) Therapeutic Vaccines Market Revenue Share, By Companies, 2024

10.2 United States (US) Therapeutic Vaccines Market Competitive Benchmarking, By Operating and Technical Parameters